Healthcare Industry News: American Medical Systems
News Release - April 17, 2014
Uroplasty Names Daniel P. Merz As Vice President Of Healthcare AffairsMINNEAPOLIS, April 17, 2014 -- (Healthcare Sales & Marketing Network) -- Uroplasty, Inc. (UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Daniel P. Merz has joined the Company as Vice President of Healthcare Affairs. In this role, he will oversee Uroplasty's strategy to educate payors and providers of the efficiency, effectiveness and overall value of the Company's products. He joins Uroplasty with fifteen years of medical device experience, specifically in driving commercial success through enhanced reimbursement, novel clinical research and efficient regulatory clearances.
Mr. Merz has a deep background in strategic planning, process reengineering and successful influence on medical organizations and reimbursement policy. Most recently, he directed the clinical affairs program at St. Jude Medical in Plymouth, Minnesota, where he was accountable for the global trans-catheter and surgical heart valve clinical programs. Prior to that, he oversaw the clinical and regulatory team supporting the global BPH capital equipment business in Minnesota and California for American Medical Systems, a leading medical device manufacturer specializing in urology and pelvic health.
Mr. Merz holds a Bachelor of Science degree from Northwestern University in Biomedical Engineering.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only commercially available, FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults. The symptoms include urinary urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.